GT Apeiron Announces Development Candidate Nomination of Brain Penetrant PRMT5 Inhibitor, GTA182, for the Potential Treatment of MTAP-Deleted Solid Cancers
October 17, 2023 07:00 ET
|
GT Apeiron LLC
GT Apeiron Therapeutics announces development candidate nomination of GTA182, a brain penetrant MTA-cooperative PRMT5 inhibitor